The Joint Interagency Task Force 401 (JIATF-401) announced today it has awarded a $5.2 million agreement to Perennial ...

Stella Hemetsberger faces Jackie Buntan at ONE Fight Night 40 on Friday, February 13, inside Lumpinee Stadium in Bangkok, ...

The Boston Red Sox surprised everyone when they signed Ranger Suarez, after missing on Pete Alonso and letting Alex Bregman walk in free agency. Now, they need to make one last move to appease their ...

Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges. Broader ...

While we may have gotten away with high-volume, high-intensity training and minimal recovery in our twenties, we lose some of that flexibility as time goes on. Gone are the days when we could down a ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

Sophomore running back Brayden McKay is having a blast sharing the Providence backfield with junior Broden Mackert. McKay feels the two complement each other perfectly. “Me and Broden have a really ...

(From left) Shichen Xu, James Tour, Alex Lathem, Karla Silva and Ralph Abdel Nour. A research team at Rice University led by James Tour has developed a two-step flash Joule heating-chlorination and ...